On May 4, 2022 Amphera B.V. reported positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Amphera’s MesoPher dendritic cell therapy. Patients, with resected pancreatic cancer who had completed standard-of-care chemotherapy, received 3 bi-weekly injections of MesoPher and booster injections at 4 and 7 months (Press release, Amphera, MAY 4, 2022, View Source [SID1234613563]). The results from this first cohort have been published in the European Journal of Cancer1.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The latest REACtiVe data showed an average Overall Survival after surgery of approximately 36 months, with 8 of 10 patients alive, which is far beyond expected survival. No disease recurrence or any tumour progression is seen in 7 of 10 patients. Remarkably, the 3 patients with disease recurrence did not demonstrate rapid tumour growth. Furthermore, the safety profile of the treatment was favourable, with only transient grade 1 and 2 adverse events.
Prof. Casper van Eijck, principal investigator on the study and author on the paper said: "These latest data should be interpreted with care, as they are from a small cohort of patients, without a control arm. Nevertheless, these are very promising results that are exceeding disease progression and survival expectations for this group of patients. We hope to confirm these observations in the expansion cohort, with first results anticipated in the fourth quarter of this year."
Ilona Enninga PhD, COO of Amphera said: "Pancreatic cancer is notoriously challenging to treat, as the historical medical literature illustrates. In this paper, the investigators consistently identified activated T-cells against autologous tumour. We believe this mechanism of action of MesoPher, the ability to activate T-cells, is central to the efficacy signal we are observing."
Rob Meijer, CEO of Amphera said: "We are very excited by this new data showing impressive survival in this challenging disease setting. It is worth noting that MesoPher has also demonstrated encouraging safety and efficacy Phase I/II data in mesothelioma, providing strong proof of concept for the application of MesoPher in multiple cancer indications. In the fourth quarter of this year, we will also see results from our pivotal Phase II/III DENIM study with MesoPher in mesothelioma next to the expansion cohort of the REACtiVe Phase 2 study."